Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

2024.01.03
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress Dr. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve antiviral treatment of hepatitis B and C. Dr. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection. In addition, Dr Wei is involved in Kidney Disease Improving Global Outcome to develop a Guideline for HCV Infection, Diagnosis, Prevention and Management in Kidney Disease and contributes to APASL for hepatitis C guideline.
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

2024.01.03
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu University conducted research on the impact of NAFLD, as confirmed by liver histopathology, and pathological changes on individuals with chronic HBV infection. The latest research findings were selected for presentation at the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023